Biomea Fusion (NASDAQ:BMEA) held its 2026 annual meeting of stockholders, with shareholders approving the election of two Class II directors and ratifying the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Michael J.M. Hitchcock, Biomea Fusion’s interim chief executive officer, called the meeting to order and presided over the formal business. Hitchcock said the meeting was conducted in accordance with the company’s bylaws and Delaware law. He also noted that notice of the meeting and the proxy statement had been mailed on or about April 27, 2026, to stockholders of record as of the close of business on April 13, 2026.
Quorum Confirmed
Hitchcock said voting was conducted virtually by proxy and written ballot through the virtual meeting platform. Stockholders who had already submitted proxies were told they did not need to take further action unless they wished to change their vote.
Class II Directors Elected
The first item of business was the election of two Class II directors to serve for a three-year term or as otherwise described in the company’s proxy statement. The nominees were Rainer M. Erdtmann and Eric Aguiar, M.D.
Hitchcock said the company’s bylaws require timely notice from any stockholder intending to nominate director candidates, and that no such notice had been received. The board unanimously recommended that stockholders vote in favor of the proposal.
The inspector of election reported that the shares present or represented and entitled to vote were voted in favor of the nominated directors.
Deloitte Appointment Ratified
Stockholders also approved the ratification of Deloitte & Touche LLP as Biomea Fusion’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Hitchcock said the audit committee, which he described as consisting entirely of independent directors, had appointed Deloitte & Touche to audit the company’s financial statements for the year. The board approved the selection and submitted it to stockholders for ratification as a matter of good corporate governance, although Hitchcock noted that stockholder ratification is not required under the company’s bylaws.
The inspector of election reported that a majority of the shares present or represented and entitled to vote supported the ratification of Deloitte & Touche.
Final Results to Be Filed With SEC
Following the voting report, Hitchcock declared that all proposals presented at the meeting had been approved or ratified by stockholders. He said final voting results, including ballots and proxies recorded during the meeting, would be included in the inspector of election’s report, recorded in the meeting minutes and filed in the company’s reports with the Securities and Exchange Commission.
With no other matters presented for consideration, Hitchcock adjourned the meeting.
About Biomea Fusion (NASDAQ:BMEA)
Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.
The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.
